Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial: The Lancet Oncology

F. Tomao, P. Vici, S. Tomao

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)616-617
Number of pages2
JournalLancet Oncol.
Volume21
Issue number5
DOIs
Publication statusPublished - 2020

Keywords

  • rucaparib
  • indole derivative
  • platinum
  • blood toxicity
  • cancer grading
  • cancer recurrence
  • disease exacerbation
  • drug dose reduction
  • drug efficacy
  • drug safety
  • fatigue
  • follow up
  • gastrointestinal toxicity
  • gene mutation
  • homologous recombination
  • human
  • intention to treat analysis
  • maintenance therapy
  • Note
  • ovary cancer
  • overall survival
  • phase 3 clinical trial (topic)
  • predictive value
  • priority journal
  • time to treatment
  • treatment interruption
  • treatment outcome
  • treatment response
  • tumor suppressor gene
  • female
  • ovary tumor
  • tumor recurrence
  • Carcinoma, Ovarian Epithelial
  • Female
  • Humans
  • Indoles
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms
  • Platinum

Cite this